Statins and biomarkers of inflammation

被引：78

作者：

Devaraj S. ^{[1
]}

Rogers J. ^{[1
]}

Jialal I. ^{[1
]}

机构：

[1] VA Northern California Health System, Laboratory for Atherosclerosis and Metabolic Research, Universiy of California Davis Medical Center, Sacramento, CA 95817

来源：

Current Atherosclerosis Reports | 2007年 / 9卷 / 1期

基金：

美国国家卫生研究院;

关键词：

Statin; Simvastatin; Atorvastatin; Pravastatin; Lovastatin;

D O I：

10.1007/BF02693938

中图分类号：

学科分类号：

摘要：

Clinical and epidemiologic studies convincingly demonstrate that increased levels of low-density lipoprotein cholesterol promote premature atherosclerosis. Several large clinical trials have demonstrated that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) decrease cardiovascular events. The beneficial effects of statins may extend to mechanisms beyond cholesterol reduction. Evidence for the pleiotropic effects of statins is provided by recent clinical trials in which the benefit of statin drugs is manifest early in the course of lipid-lowering therapy, well before plaque regression could occur. Inflammation is pivotal in all stages of atherosclerosis, and C-reactive protein (CRP), the prototypic marker of inflammation, has emerged as a cardiovascular risk marker. Statins reduce CRP levels, and this reduction in most studies does not correlate to reduction in cholesterol. In addition, statins have beneficial effects on endothelial function, monocytemacrophages, and platelets. In this review we discuss the role of inflammation in atherosclerosis, the role of CRP as a risk marker, the clinical evidence implicating the anti-inflammatory effects of statins, and the cellular and molecular basis underlying the anti-inflammatory effects of statins. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：33 / 41

页数：8

共 71 条

[51] Weber C., Erl W., Weber P.C., HMGCoA reductase inhibitors decrease CD11b expression and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia, J Am Coll Cardiol, 30, pp. 1212-1217, (1997)
[52] Ferro D., Parrotto S., Basili S., Et al., Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia, J Am Coll Cardiol, 36, pp. 427-431, (2000)
[53] Bustos C., Hernandez-Presa M.A., Ortego M., Et al., HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis, J Am Coll Cardiol, 32, pp. 2057-2064, (1998)
[54] Rezai Majd A., Maca T., Bucek R.A., Et al., Simvastatin reduces expression of cytokines IL-6,IL-8 and MCP-1 in circulating monocytes from hypercholesterolemic patients, Arterioscler Thromb Vasc Biol, 22, pp. 1194-1199, (2002)
[55] Colli S., Eligini S., Lalli M., Et al., Vastatins inhibit tissue factor in cultured human macrophages: A novel mechanism of protection against atherothrombosis, Arterioscler Thromb Vasc Biol, 17, pp. 265-272, (1997)
[56] Devaraj S., Chan E., Jialal I., Direct demonstration of the antiinflammtory effects of simvastatin in patients with metabolic syndrome, J Clin Endocrinol Metab, (2006)
[57] Mohiuddin I., Chai H., Lin P.H., Et al., Nitrotyrosine and chlorotyrosine: Clinical significance and biological functions in the vascular system, J Surg Res, 133, pp. 143-149, (2006)
[58] Shishehbor M.H., Aviles R.J., Brennan M.L., Et al., Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy, JAMA, 289, pp. 1675-1680, (2003)
[59] Nicholls S.J., Hazen S.L., Myeloperoxidase and cardiovascular disease, Arterioscler Thromb Vasc Biol, 25, pp. 1102-1111, (2005)
[60] Shishehbor M.H., Brennan M.L., Aviles R.J., Et al., Statins promote potent systemic antioxidant effects through specific inflammatory pathways, Circulation, 108, pp. 426-431, (2003)

← 1 2 3 4 5 6 7 8 →